Transforming medical device clinical trials with agentic AI: a Taiwan-specific framework integrating smart data, regulatory evidence, and trial optimization
Frontiers in Digital Health · 30.10.2026 · 8
DOI: 10.3389/fdgth.2026.1934685 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Digital Health, online erschienen am 30.10.2026. Verfasst von Wo Yun Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Industry Master and Ph.D. Program, Chang Gung University, Taoyuan, Taiwan. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Medical device clinical trials present distinctive regulatory and methodological challenges—including device-specific classification, engineering-based endpoints, operator-dependent performance, device-related safety considerations, and lifecycle evidence obligations—that differ from those of pharmaceutical trials. In our structured synthesis, we identified no published framework that explicitly integrates agentic AI into medical device clinical-trial workflows within Taiwan's regulatory context. Drawing on a structured synthesis of 39 core sources (29 scholarly publications and 10 regulatory or standards documents), supplemented by targeted contextual literature on AI governance and implementation, we developed a five-layer framework comprising Regulatory Decision, Evidence Requirement, Data Integration, Agentic AI Optimization, and Adaptive Feedback. The framework links bounded agentic AI functions to TFDA regulatory decision-making, device-specific evidence requirements, device-derived and real-world data, and lifecycle evidence generation. Cross-cutting governance considerations include algorithmic bias and representativeness, transparency and traceability, human oversight and accountability, cybersecurity and privacy, and model-drift and lifecycle change management. The framework is a contextual proposal for Taiwan rather than a validated or implemented system. We provide actionable recommendations for regulators, investigators, AI developers, and infrastructure planners. External assessment and prospective feasibility testing are required before implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotechnology Industry Master and Ph.D. Program, Chang Gung University, Taoyuan, Taiwan.
- Blue Blood Biotech Corp., Taipei, Taiwan.
- Sanar Biotech Corp., Taipei, Taiwan.
- Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
Zitieren
APA
Lee, W. Y., Lin, C. C., Young, G. H., & Wang, R. Y. L. (2026). Transforming medical device clinical trials with agentic AI: a Taiwan-specific framework integrating smart data, regulatory evidence, and trial optimization. Frontiers in Digital Health, 8. https://doi.org/10.3389/fdgth.2026.1934685
Vancouver
Lee WY, Lin CC, Young GH, Wang RYL. Transforming medical device clinical trials with agentic AI: a Taiwan-specific framework integrating smart data, regulatory evidence, and trial optimization. Frontiers in Digital Health. 2026;8. doi:10.3389/fdgth.2026.1934685
BibTeX
@article{Lee2026,
author = {Lee, Wo Yun and Lin, Chien-Chen and Young, Guang-Huar and Wang, Robert Y L},
title = {Transforming medical device clinical trials with agentic AI: a Taiwan-specific framework integrating smart data, regulatory evidence, and trial optimization},
journal = {Frontiers in Digital Health},
year = {2026},
volume = {8},
doi = {10.3389/fdgth.2026.1934685}
}
EUVIMED